Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
Open accessThe DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) act by increasing insulin secretion, decreasing glucagon secretion, slowing gastric emptying, and increasing satiety. OBJECTIVE: Published evidence directly comparing GLP-1RAs with other approved treatments for type 2 diabetes (T2D) was systematically reviewed. METHODS: A literature search was performed using MEDLINE and Embase databases to identify papers comparing GLP-1RAs with other classes of glucose-lowering therapy in patients with T2D. RESULTS: Of the 1303 papers identified, 57 met the prespecified criteria for a high-quality clinical trial or retrospective study. The efficacy and tolerability of approved GLP-1RAs (exenatide twice daily or once weekly, dulaglutide, liraglutide, lixisenatide, and albiglutide) were compared with insulin products (23 prospective studies + seven retrospective studies), dipeptidyl peptidase-4 inhibitors (11 prospective studies + three retrospective studies), sulfonylureas (nine prospective studies + one retrospective study), thiazolidinediones (five prospective studies), and metformin (two prospective studies). GLP-1RAs are effective as a second-line therapy in improving glycemic parameters in patients with T2D. Reductions in glycated hemoglobin from baseline with GLP-1RAs tended to be greater or similar compared with insulin therapy. GLP-1RAs were consistently more effective in reducing body weight than most oral glucose-lowering drugs and insulin and were associated with lower hypoglycemia risk versus insulin or sulfonylureas. GLP-1RAs improved cardiovascular risk factors, and preliminary data suggest they improve cardiovascular outcomes in patients with T2D compared with oral glucose-lowering drugs. However, results from ongoing studies are awaited to confirm these early findings. CONCLUSION: This systematic review found that GLP-1RAs are an effective class of glucose-lowering drugs for T2D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 analogues also induce weight loss, which is associated with improved T2D prognosis.252,262,263”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [262]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In trials analyzing the addition of an injectable GLP-1 RA, dual GIP and GLP-1 RA, or insulin in people needing further glucose lowering, glycemic efficacies of GLP-1 RAs and the dual GIP and GLP-1 RA were similar to or greater than that of basal insulin (123-130).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [125]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 RAs and dual GIP and GLP-1 RA in these trials also had a lower risk of hypoglycemia and beneficial effects on body weight compared with insulin, albeit with greater gastrointestinal side effects.”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [125]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 RAs and dual GIP and GLP-1 RA in these trials also had a lower risk of hypoglycemia and beneficial effects on body weight compared with insulin, albeit with greater gastrointestinal side effects.”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [125]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 RAs and dual GIP and GLP-1 RA in these trials also had a lower risk of hypoglycemia and beneficial effects on body weight compared with insulin, albeit with greater gastrointestinal side effects.”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [125]
Experimental — accuracy not yet measured
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Projections of Global Mortality and Burden of Disease from 2002 to 2030
Mathers, C. D., & Loncar, D. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030442 · Cited by 11,386
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 1×
“postprandial glucose excursions, and some cardiovascular risk factors, without increasing the risk of hypoglycemia.(4) Clinical trials have also studied the effects of GLP-1RA therapy on cardiovascular outcomes in patients with T2D.”
BackgroundLixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 10×
“Conclusion: This systematic review found that GLP-1RAs are an effective class of glucoselowering drugs for T2D.”
BackgroundInfluentialNauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Cited by
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
“Evidence from trials comparing GLP-1 receptor agonists and insulin (basal, premixed, or basal-bolus) shows similar or even better efficacy in HbA1c reduction (212,213).”
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s009 · Cited by 914
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s009 · Cited by 662
Reed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441
9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
Doyle-Delgado, K., Chamberlain, J. J., Shubrook, J. H., Skolnik, N., & Trujillo, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-2470 · Cited by 111
GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date
Brunton, S. A., & Wysham, C. H. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1798099 · Cited by 80
Liraglutide repairs the infarcted heart: The role of the SIRT1/Parkin/mitophagy pathway
Qiao, H., Ren, H., Du, H., Zhang, M., Xiong, X., & Lv, R. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8371 · Cited by 79
RetractedRomera, I., Cebrián-Cuenca, A., Álvarez-Guisasola, F., Gomez-Peralta, F., & Reviriego, J. (2019) · Diabetes Therapy · doi:10.1007/s13300-018-0535-9 · Cited by 77
Rosenstock, J., Emral, R., Sauque-Reyna, L., Mohan, V., Trescolí, C., Al Sifri, S., Lalic, N., Alvarez, A., Picard, P., Bonnemaire, M., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0393 · Cited by 63
“GLP-1 RA therapy can be associated with gastrointestinal (GI) adverse events (AEs) and resultant adherence issues (4).”
BackgroundLandgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Reuter, H.-M., & Siegel, E. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1018-9106 · Cited by 62
“They can lower plasma glucose more on average than oral antidiabetics and also have blood pressure-lowering (slight), weightreducing [106] and specific cardio- and renal protective (see below) effects.”
Tran, S., Retnakaran, R., Zinman, B., & Kramer, C. K. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13137 · Cited by 51
Xie, X., Yang, S., Deng, S., Liu, Y., Xu, Z., & He, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1613610 · Cited by 57
Patient preferences for glucagon-like peptide-1 receptor–agonist treatment attributes
Thieu, V. T., Robinson, S., Kennedy-Martin, T., Boye, K. S., & Garcia-Perez, L.-E. (2019) · Patient Preference and Adherence · doi:10.2147/ppa.s187907 · Cited by 47
Alexander, J. T., Staab, E. M., Wan, W., Franco, M. I., KNITTER, A. C., Skandari, M. R., Bolen, S. D., Maruthur, N. M., Huang, E. S., Philipson, L. H., et al. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-021-07105-9 · Cited by 46
Tao, Y., Ge, G., Wang, Q., Wang, W., Zhang, W., Bai, J., Lin, J., Shen, J., Guo, X., Xu, Y., et al. (2019) · IUBMB Life · doi:10.1002/iub.2031 · Cited by 44
Overbasalization: Addressing Hesitancy in Treatment Intensification Beyond Basal Insulin
Cowart, K. (2020) · Clinical Diabetes · doi:10.2337/cd19-0061 · Cited by 33
King, A., & Miller, E. M. (2022) · Clinical Diabetes · doi:10.2337/cd22-0027 · Cited by 34
Zhang, R., Hou, Q., Li, B., Deng, L., Yang, Y., Li, T.-X., Yao, X., Yang, L.-L., Lin, X.-L., Liao, Y.-Q., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1132004 · Cited by 41
Bonora, B. M., Rigato, M., Frison, V., D'Ambrosio, M., Tadiotto, F., Lapolla, A., Simioni, N., Paccagnella, A., Avogaro, A., & Fadini, G. P. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108686 · Cited by 27
The use of GLP‐1 receptor agonists in hospitalised patients: An untapped potential
Mustafa, O. G., & Whyte, M. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3191 · Cited by 27
Alexopoulos, A.-S., & Buse, J. B. (2019) · Metabolism · doi:10.1016/j.metabol.2019.06.012 · Cited by 24
Doğruel, H., & Balcı, M. K. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i8.446 · Cited by 28
Davies, M. J., Bianchi, C., & Del Prato, S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154242 · Cited by 23
Landgraf, R., Kellerer, M., Fach, E.-M., Gallwitz, B., Hamann, A., Joost, H., Klein, H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., et al. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-115964 · Cited by 24
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., & Siegel, E. G. (2020) · Diabetologie und Stoffwechsel · doi:10.1055/a-1193-3793 · Cited by 33
Robinson, S. J., Boye, K. S., Mody, R., Strizek, A., Кониг, М., Malik, R., & Kennedy‐Martin, T. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00839-5 · Cited by 25
Norrbacka, K., Sicras‐Mainar, A., Lebrec, J., Artime, E., Díaz‐Cerezo, S., Tofé, S., Hernández, I., & Romera, I. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01039-5 · Cited by 21
Mata‐Cases, M., Franch‐Nadal, J., Ortega, E., Real, J., Gratacòs, M., Vlacho, B., & Mauricio, D. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1618806 · Cited by 18
Shang, P., Baker, M. R., Banks, S. A., Hong, S., & Choi, D. (2021) · Journal of Movement Disorders · doi:10.14802/jmd.21035 · Cited by 17
Asiabar, A. S., Rezaei, M. A., Jafarzadeh, D., Rajaei, S., Atefimanesh, P., Soleimanpour, S., Meher, M. H. K., & Azari, S. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03755-w · Cited by 22
Glucagon-like Peptide-1 Receptor Agonists
Jeon, J. Y., & Kim, H. J. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_14 · Cited by 16
Handelsman, Y., Wyne, K., Cannon, A., Shannon, M., & Schneider, D. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.9-a.s14 · Cited by 14
Baxter, M., Morimoto, Y., Tamiwa, M., Hattori, M., Peng, X., LUBWAMA, R. N., & Maegawa, H. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00836-8 · Cited by 16
Fiore, V., Carbotta, G., Barraco, S., Falasca, P., Aricò, C. N., & Barucca, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16174 · Cited by 17
Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications
Heile, M., Wyne, K., Billings, L., Cannon, A., Handelsman, Y., & Shannon, M. H. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.9-a.s42 · Cited by 14
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1624-3449 · Cited by 12
Zargar, A. A., Mehta, V., Huddar, V., Gupta, R., Bhandari, K., Posa, M. K., Ramya, T. S., Snigdha, D., Vijayakumar, B., Sharma, M. C., et al. (2025) · Current Proteomics · doi:10.1016/j.curpro.2025.100014 · Cited by 25
Kaneto, H., Koshida, R., & Baxter, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14095 · Cited by 12
Novel ABCA1 peptide agonists with antidiabetic action
Azhar, S., Bittner, S., Hu, J., Shen, W., Cortez, Y., Xiao, H., Han, L., Lagerstedt, J. O., Kraemer, F. B., & Johansson, J. O. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.09.011 · Cited by 11
Dulaglutide and Insulin: How Can the AWARD Studies Help Guide Clinical Practice?
MacIsaac, R. J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00863-5 · Cited by 13
Current Status of Therapeutic Peptides for the Management of Diabetes Mellitus
Prajapati, A., Rana, D., Rangra, S., Jindal, A. B., & Benival, D. M. (2024) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-024-10590-1 · Cited by 10
Real-life experience with Dulaglutide: Analysis of clinical effectiveness to 24 months
Obregón, F. M., Miramontes‐González, J. P., Guajardo-Fajardo, C. R., Nieto, Á. L. M., López-Suárez, J., Martín‐Vallejo, J., Prados, Y. A., de Lucas, M. D. G., & Jiménez, D. L. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107916 · Cited by 12
From Current Therapeutics to Multitarget Ligands: A Review of Diabetes Pharmacological Treatments
Cabré, F., Centelles, J. J., & Cascante, M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091125 · Cited by 15
Manejo de la hiperglucemia con fármacos no insulínicos en pacientes adultos con diabetes tipo 2
Guisasola, F. Á., Orozco‐Beltrán, D., Cuenca, A. M. C., Quintero, M. A. R., Angullo-Martínez, E., Lachica, L. Á., Millán, C. O., Caride-Miana, E., Navarro-Pérez, J., Pérez, J. S., et al. (2019) · Atención Primaria · doi:10.1016/j.aprim.2019.05.014 · Cited by 19
An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus
Novodvorský, P., & Haluzík, M. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1978974 · Cited by 13
Kim, K., Unni, S. K., McAdam‐Marx, C., Thomas, S. M., Sterling, K. L., Olsen, C. J., Johnstone, B. M., Mitchell, M., & Brixner, D. I. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.25.3.314 · Cited by 11
Rasalam, R. R., Barlow, J., Kennedy, M., Phillips, P., & Wright, A. F. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0642-2 · Cited by 11
Franch‐Nadal, J., Mata‐Cases, M., Ortega, E., Real, J., Gratacòs, M., Vlacho, B., Vallés, J. A., & Mauricio, D. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091389 · Cited by 8
Xu, J., Yao, D., & Xia, J. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13398 · Cited by 11
Song, R., Qian, H., Wang, Y., Li, Q., Li, D., Chen, J., Yang, J., Zhong, J., Yang, H., Min, X., et al. (2022) · Journal of Diabetes Research · doi:10.1155/2022/4554996 · Cited by 10
Kamalinia, S., Josse, R. G., Donio, P. J., Leduc, L., Shah, B. R., & Tobe, S. W. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.100 · Cited by 7
Small-Molecule GLP-1 Receptor Agonists: A Promising Pharmacological Approach
Șeremet, O. C., Pușcașu, C., Andrei, C., Nițulescu, G., Zbârcea, C. E., & Olaru, O. T. (2025) · Medicina · doi:10.3390/medicina61111902 · Cited by 12
Bellido, D., Galiana, P. A., Palomar, J. M. R., Sintes, R. A., Nubiolae, A., Bellido, V., & Romero, G. Z. (2018) · Current Therapeutic Research · doi:10.1016/j.curtheres.2018.09.001 · Cited by 7
Stimulus for Glucagon-Like Peptide 1 Secretion in Rats
Natochin, Y. V., Кутина, А. В., Marina, A. S., & Ei, S. (2018) · Doklady Biological Sciences · doi:10.1134/s0012496618020084 · Cited by 6
Meneghini, L., Doshi, A., Gouet, D., Vilsbøll, T., Begtrup, K., Örsy, P., Ranthe, M. F., & Lingvay, I. (2019) · Diabetic Medicine · doi:10.1111/dme.14178 · Cited by 6
Evidence-based therapeutics for hyperglycemia in hospitalized noncritically ill patients
Gracia‐Ramos, A. E., Carretero‐Gómez, J., Mendez, C. E., & Carrasco-Sánchez, F. J. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1997288 · Cited by 7
Terauchi, Y., Usami, M., & Inoue, T. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02121-5 · Cited by 7
Gilbert, M. P., Skelly, J. M., Hernandez, A. F., Green, J. B., Krychtiuk, K. A., Granger, C. B., Leiter, L. A., McMurray, J. J. V., Prato, S. D., & Pratley, R. E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15479 · Cited by 7
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6755 · Cited by 7
Wang, L., Liu, X., Yang, W., Lai, J., Yu, X., Liu, J., Gao, X., Ming, J., Ma, K., Xu, J., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00904-z · Cited by 7
Recent Updates on Glucagon-Like Peptide 1 Receptor Agonist
Kim, H. J. (2021) · Journal of Korean Diabetes · doi:10.4093/jkd.2021.22.2.126 · Cited by 7
Joshi, N., Baloch, K. M., Rukh, S., Khan, A. M., Muskan, F., Kumari, V., Khan, H., Zeeshan, M., Azam, G., Khalid, S., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002712 · Cited by 6
Kuang, J., Zhu, J., Liu, S., & Li, Q. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00910-1 · Cited by 5
Coke, L. A., DEEDWANIA, P. C., Hinnen, D., Magwire, M., & Miller, N. H. (2022) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000661 · Cited by 6
Granhall, C., Bækdal, T. A., Breitschaft, A., Søndergaard, F. L., Anderson, T. W., & Thomsen, M. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01106-x · Cited by 4
Lee, J., Kim, H. S., Jung, C. H., Park, J., & Lee, W. J. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3466 · Cited by 4
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00921-5 · Cited by 8
Total synthesis and absolute structure of N55, a positive modulator of GLP-1 signaling
Lin, N.-P., & Chein, R. (2020) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob01722a · Cited by 4
Rabbani, S. A., Saini, M., El-Tanani, M. E.-T., Kumar, R., Matalka, I. I., El‐Tanani, Y., Sharma, S., & Rizzo, M. (2026) · Pharmaceuticals · doi:10.3390/ph19050732 · Cited by 5
Rajput, R., Sinha, B., Lodha, S., Deb, P., Das, S., Agarwal, S., Das, A. K., & Thomas, N. (2022) · Clinical Diabetology · doi:10.5603/dk.a2022.0026 · Cited by 6
Revolutionizing diabetes care: unveiling tirzepatide’s potential in glycemic control and beyond
Sood, A., Kaur, P., Syed, O., Sood, A., Aronow, W. S., Borokhovsky, B., Bhatia, V., & Gupta, R. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2310070 · Cited by 4
Sugimoto, K., Tanaka, Y., Sozu, T., Nishiyama, H., Hoshino, T., Watanabe, Y., Tamura, A., Ohta, S., Yamazaki, T., Suzuki, S., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00814-0 · Cited by 3
Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease
Niezen, S., del Castillo, H. D., Castaner, L. A. M., & Fornoni, A. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.72 · Cited by 2
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., & Siegel, E. G. (2020) · Der Diabetologe · doi:10.1007/s11428-020-00608-9 · Cited by 2
Kaneto, H., Baxter, M., Takahashi, Y., & Terauchi, Y. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02311-1 · Cited by 1
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01047-y · Cited by 2
Malighetti, M. E., Vescini, F., Carpentieri, M. S., Altomari, A., Turchi, F., Porto, A. D., & Dauriz, M. (2025) · Minerva Endocrinology · doi:10.23736/s2724-6507.25.04376-3 · Cited by 1
Balakumar, P., Khan, N. A., Easwaran, V., & Orayj, K. M. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113155 · Cited by 1
A Narrative Review of the Metabolic Benefits of GLP-1 and GIP Receptor Agonists in Obesity
Lee, A.-H., & Holmes-Walker, D. J. (2026) · Healthcare · doi:10.3390/healthcare14060734 · Cited by 2
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Die Diabetologie · doi:10.1007/s11428-023-01144-y · Cited by 1
Blonde, L., & Fonseca, V. A. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0293 · Cited by 2
Die neue individuelle antihyperglykämische Therapie bei Typ-2-Diabetes
Konz, K. (2019) · Info Diabetologie · doi:10.1007/s15034-019-1561-z
Torkos, S., Burke, J. M., & Zaiken, K. (2020) · Journal of Pharmacy Technology · doi:10.1177/8755122520949449
Introducing a novel therapy for type 2 diabetes to primary care
Brunton, S. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1798686
Focus on New Diabetes Treatment Options with Cardiovascular Benefits
Jun, J. K. (2019) · Journal of Contemporary Pharmacy Practice · doi:10.37901/jcphp18-00029
Bando, H., Iwatsuki, N., Sakamoto, K., & Ogawa, T. (2020) · doi:10.52588/case-reports-medical-research.1.05
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., & Siegel, E. G. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00765-5
McGill, J. B. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.9-a.s3
Diabetes Mellitus Type 2, Prediabetes, and Chronic Heart Failure
Mirzazada, V., kizi, S. S. S., Ismayilova, N., Huseynova, A., Nurmammadova, G., Ismayilova, S., & Aliyeva, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106391
Iriowen, R., Edema, T. F., Dike, V., Ogundipe, T., Oluwatowoju, I., Nwatamole, B. C., Okonkwo, O. A., & Okobi, O. E. (2023) · American Journal of Health Medicine and Nursing Practice · doi:10.47672/ajhmn.1586 · Cited by 2
¿Qué nos han demostrado los arGLP-1 en el abordaje integral temprano?
García, M. C. G., & Lachica, L. Á. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.manejointegral.art3
Ha, K. H., Kim, W., Kim, D., & Kim, D. J. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.108983
Pharmacologic Therapy for Type 2 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch04
Metadata
- Authors
- Levin, P. A., Nguyen, H., Wittbrodt, E., & Kim, S. C.
- Affiliations
- AstraZeneca (United States) (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Kim, Seoyoung C.
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2017-04
- Volume
- Volume 10
- Pages
- 123-139
- ISSN
- 1178-7007 (ISSN-L)
- PMC
- PMC5389657
- OpenAlex
- W2604317643
- Cited by
- 107
- References
- 78
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 8 · 2023: 5 · 2022: 10 · 2021: 15 · 2020: 19 · 2019: 18 · 2018: 14 · 2017: 1
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, comparative effectiveness, glycemic control, HbA1c, insulin therapy, DPP-4 inhibitors, sulfonylureas, thiazolidinediones, metformin, weight loss, hypoglycemia, cardiovascular outcomes, exenatide, dulaglutide, liraglutide, lixisenatide, albiglutide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.